Delivery Order SPE2DB22D2206-SPE2DB25FHW76
- Not listed
- The Defense Logistics Agency awarded a $21,057.57 delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 11, 2025. AmerisourceBergen will perform this delivery order from its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,101.10 to AmerisourceBergen Drug Corp on July 24, 2025, for 12,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, carrying an ultimate completion date of July 25, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply contract. This...
- The Defense Logistics Agency awarded a delivery order valued at $70,439.09 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme supplement) in 100-count bottles. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price and an ultimate completion date of September 3, 2025. AmerisourceBergen will perform this delivery order from its corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order valued at $9,025.18 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,860.27 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancrelipase) in 100-count bottles. This competitive, firm fixed-price delivery order, with an ultimate completion date of September 11, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles, valued at $9,164.04. This competitively awarded, firm fixed-price delivery order, with no set-aside designation, is scheduled for completion by September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for 36,000 units of Creon DR 100s capsules, a pancreatic enzyme replacement medication. This firm fixed-price delivery order, valued at $11,775.31, represents a competitively awarded contract with an ultimate completion date of August 29, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied to...
- The Defense Logistics Agency awarded a $2,376.88 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of 36,000 unit capsules of Creon 100s, a pancreatic enzyme replacement therapy. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order valued at $2,385.77 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This is a firm fixed price, non-set-aside competitive award with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major healthcare...
- The Defense Logistics Agency awarded a $2,099.20 delivery order to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s, a pancreatic enzyme replacement medication. This firm fixed-price, non-set-aside contract is scheduled for completion by August 14, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FHW76Delivery Order
The Defense Logistics Agency issued a delivery order valued at $14,994.54 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packages. This firm fixed-price delivery order, awarded on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a non-competitive award under an existing contract vehicle. The pharmaceutical will be supplied from the vendor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to military healthcare programs and other federal healthcare systems. AmerisourceBergen's selection as a DLA prime vendor reflects its established capability to meet federal medical procurement requirements and support the Defense Health Agency and other government healthcare customers through flexible contracting mechanisms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 7/14/25 |